HoLISTIC Abstracts
Creation of a multistate model to improve prognostication across the disease course in advanced stage classic Hodgkin lymphoma (cHL): A Report from the HoLISTIC Consortium.
Rodday AM*, Parsons SK* (*co-first authors), Cui ZJ, Xiang Q, Counsell N, Rossetti, Upshaw JN, Williams ALM, Kirkwood AA, Li H, Cerhan JR, Federico M, Friedberg JW, Gallamini A, Hawkes EA, Hodgson D, Johnson P, Link BK, Mou E, Radford J, Savage KJ, Stephens DM, Zinzani PL, Maurer MJ, Evens AM.
Accepted for oral presentation, 66th annual meeting of the American Society of Hematology. San Diego, CA. December 2024.
Identification of Risk Categories and Stratification from the Advanced-Stage Hodgkin Lymphoma (AS-HL) International Prognostic Index (A-HIPI) Model.
Maurer M, Parsons SKP, Upshaw J, Rodday AM, Friedberg, JW, Gallamini A, Federico M, Hawkes E, Hodgson D, Johnson P, Mou E, Savage K, Zinzani PL Evens A.
Presented at the International Symposium on Hodgkin Lymphoma (ISHL13). Cologne, Germany. October 2024.
Exploring the capability of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index to predict the lack of an early complete metabolic response in a multicentric Italian cohort.
Cellini A, Assanto GM, Romano A, Santuccio G, Vitale C, Montalbano MC, Cavarretta CA, Angotzi F, Ruocco V, Serafin A, Danesin N, Coscia M, Di Raimondo F, Giudice ID, Piazza F, Trentin L, Visentin A.
Presented at the International Symposium on Hodgkin Lymphoma (ISHL13). Cologne, Germany. October 2024.
Development and validation of the Early stage (ES) classic Hodgkin Lymphoma (cHL) International Prognostication Index (E-HIPI): an individualized prediction model for progression-free survival (PFS) utilizing objective and continuous variables.
Rodday AM, Radford J, Maurer M.J, Upshaw J, Counsell N, Rossetti S, Advani R, Andre M, Chang C, Gallamini A, Hay AE, Hodgson DC, Hoppe R, Hutchings M, Johnson P, Mou E, Opat S, Raemaekers J, Savage KJ, Xiang Q, Parsons SK, Evens AM.
Presented at the International Symposium on Hodgkin Lymphoma (ISHL13). Cologne, Germany. October 2024.
Identification of Risk Categories from the Advanced-Stage Hodgkin International Prognostic Index (A-HIPI) Model: A Detailed Analysis from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
Maurer MJ, Parsons SK, Upshaw J, Friedberg JW, Gallamini A, Federico M, Hawkes EA, Hodgson D, Johnson P, Link BK, Savage KJ, Zinzani PL, Evens AM
Blood (2023) 142 (Supplement 1): 3067-3069.
External Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI): Strong Calibration in the Brazilian Prospective Hodgkin Lymphoma Registry
Biasoli I, Buccheri V, Moreira FR, Castro N, Vilarim CC, Traina F, Chiattone C, Praxedes M, Solza C, Perobelli L, Baiocchi O, Gaiolla R, Boquimpani C, Sola CB, Silva RO, Ribas AC, Pagnano K, Steffenello G, De Souza C, Spector N, Rodday AM, Upshaw J, Maurer MJ, Evens AM, Parsons SK
Blood (2023) 142 (Supplement 1): 6200-6202.
Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
Evens AM, Rodday, AM, Maurer MJ, Advani RH, Andre M, Gallamini A, Hay AE, Hodgson D, Hoppe RT, Hutchings M, Johnson P, Link BK, Opat S, Raemaekers JM, Upshaw J, Xiang Q, Counsell N, Parsons SK, Radford J
Blood (2023) 142 (Supplement 1): 3058-3060.
Age-Based Validation of the Advanced-Stage Hodgkin Lymphoma International Prognostic Index (A-HIPI) in a Real-World Danish Study: Suboptimal Performance in Older Patients
Jørgensen RRK, Eloranta S, Christensen JH, Hutchings M, Dahl-Soerensen RB, Kamper P, Evens AM, Maurer MJ, Parsons SK, Rodday AM, Upshaw J, El-Galaly TC, Jakobsen LH
Blood (2023) 142 (Supplement 1): 4455-4456.
Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
Rodday AM, Parsons SK, Friedberg JW, Gallamini A, Hawkes E, Hodgson DC, Johnson P, Link BK, Mou E, Savage KJ, Upshaw J, Zinzani PL, Maurer MJ, Evens AM
Blood (2022) 140 (Supplement 1): 760–762.
Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium.
Rodday AM, Parsons SK, Scharman C, Advani R, Federico M, Friedberg JW, Gallamini A, Hodgson DC, Hoskin P, Hutchings M, Johnson P, Kelly KM, , Link BK, Radford JA, Zinzani PL, Cerhan JR, Raemaekers J, Evens AM.
Presentation at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition. December 2020.
Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).
Parsons SK, Bhakta N, Rodday AM, Scharman C, Andre M, Federico M, Friedberg JW, Friedman DL, Gallamini A, Hay AE, Kahl BS, Keller FG, Kelly KM, Meyer RM,Evens AM.
Accepted at the American Society of Clinical Oncology Meeting, June 2020.
The Hodgkin Lymphoma International Study for Individual Care (HoLISTIC): A Multi-National Collaborative to Enhance Decision Making for Pediatric and Adult Hodgkin Lymphoma (HL).
Evens A, Advani R, Aleman B, Andre M, Bhakta N, Cardoso M, Castellino S, Cerhan J, Chao C, Cohen J, Cole P, Engert A, Federico M, Figueroa L, Flerlage J, Flowers C, Fortpied C, Friedberg J, Friedman D, Gallamini A, Gutierrez M, Hahn T, Hay A, Henderson T, Hodgson D, Hoppe B, Hoppe R, Hoskin P, Hudson M, Hutchings M, Johnson P, Keller F, Kelly K, Kostakoglu L, Kumar A, Link B, Link M, Mailhot R, Meyer R, Morton L, Ng A, Radford J, Raemaekers J, Robison L, Rodday AM, Savage K, Schwartz C, Specht L, Straus D, Upshaw J, Leeuwe FV, Volchenboum S, Warwick L, Wong J, Wong L, Zinzani PL, Parsons S.
Poster Presentation European Hematology Association. June 2020.
BACKGROUND
Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL).
Kumar AJ, Nelson J, Rodday AM, Evens AM, Friedberg JW, Wildes TM, Parsons SK.
Presentation at 62nd American Society of Hematology (ASH) Annual Meeting & Exposition. December 2020.
The Role of Immortal Time Bias in Assessing the Relationship between Treatment Intensity and Survival in Hodgkin Lymphoma: An Analysis of Surveillance, Epidemiology and End Result (SEER) Medicare Data.
Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK.
Accepted at Academy Health Annual Research Meeting, June 2020
An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.
Castellino SM, LeBlanc ML, Herrera AF, Parsons SK, Punnet, A, Hodgson DC, Rutherford SC, Khan N, Constine LS, Davison K, Prica AA, Friedberg FW, Kelly, KM.
Accepted at the American Society of Clinical Oncology Meeting, June 2020.
Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens.
Rodday AM, Hahn TE, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK.
Blood. 2019;134(Supplement_1):1563-. doi: 10.1182/blood-Nov 2019-124141.
Performance of FACT-GOG-Ntx to Assess Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Pediatric Hodgkin Lymphoma (HL) Patients.
Castellino SM, Rodday AM, Pei Q, Bush R, Keller FG, Henderson TO, Kelly KM, Cella D, Parsons SK.
Accepted for presentation at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL. June 2019.
Performance of FACT-GOG-Ntx to Assess Chemotherapy-Induced Peripheral Neuropathy (CIPN) in Pediatric Hodgkin Lymphoma (HL) Patients.
Castellino SM, Rodday AM, Pei Q, Bush R, Keller FG, Henderson TO, Kelly KM, Cella D, Parsons SK.
Accepted for presentation at 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Chicago, IL. June 2019.
Disparities in First-line Treatment of Elderly Patients with Hodgkin Lymphoma: An Analysis of Surveillance, Epidemiology and End Results (SEER)-Medicare Data.
Rodday AM, Hahn T, Lindenauer PK, Friedberg J, Evens AM, Parsons SK.
Accepted for presentation at Academy Health 2019 Annual Research Meeting. Washington, DC. June 2019.
Hematopoietic Stem Cell Transplant Utilization in Relapsed/Refractory HL: A Population Level Analysis of Statewide Claims Data.
Waheed A, Rodday AM, Kumar AJ, Miller K, Parsons SK.
Blood, 132(Suppl 1), 4771-4771. doi: 10.1182/blood-2018-99-111921. Presentation at 60th American Society of Hematology (ASH) Annual Meeting & Exposition. San Diego, CA. December 2018.
Productivity loss among parent caregivers is associated with poor health related quality of life (HRQL) at the time of the initial diagnosis of advanced stage Hodgkin Lymphoma (HL).
Parsons SK, Castellino SM, Rodday AM, Keller F, Curtis R, Kelly K, Conti R, Lerner D, Henderson TO.
Oral Presentation at 60th American Society of Hematology (ASH) Annual Meeting & Exposition. San Diego, CA. December 2018. Blood, 132(Suppl 1), 975-975. doi: 10.1182/blood-2018-99-117316.
The Development and Validation of an Electronic health record (EHR)-based Algorithm for Identifying Treatment Failure in Newly Diagnosed Hodgkin lymphoma (HL) treated in a US Community Oncology Setting.
Chao C, Xu L, Canizarro NT, Rodday AM, Feliciano J, Kumar AJ, Evens AM, Parsons SK.
Presentation at 60th American Society of Hematology (ASH) Annual Meeting & Exposition. San Diego, CA. December 2018. Blood, 132(Suppl 1), 2261-2261. doi: 10.1182/blood-2018-99-112225.
Health-Related Quality of Life (HRQL) Trajectories during Treatment for Advanced Stage Pediatric Hodgkin Lymphoma (HL).
Parsons SK, Rodday AM, Bush R, Pei Q, Curtis R, Keller F, Kelly K, Henderson T, Castellino SM.
Presentation at 60th American Society of Hematology (ASH) Annual Meeting & Exposition. San Diego, CA. December 2018. Blood, 132(Suppl 1), 3587-3587. doi: 10.1182/blood-2018-99-112664.